Abstract：Objective: To investigate the efficacy of trastuzumab in combination with ixabepilone treatment of advanced metastatic breast cancer. Methods: 92 patients with HER-2 positive advanced breast cancer patients in our hospital were selected, the control group (45 cases) with trastuzumab treatment, study group (47 cases) with trastuzumab combined with ixabepilone treatment. The clinical efficacy was compared between the two groups. Results: After treatment, the total effective rate of treatment group was significantly higher than the control group, the difference was statistically significant (P < 0.05); For the disease control rate of two groups, disease control rate of study group was significantly higher than the control group, the difference was statistically significant (P < 0.05); For the patients of two groups before treatment, the level of serum tumor markers in comparison, no statistically significant difference (P > 0.05); after treatment, patients with serum levels of tumor markers of two groups were lower than before treatment; compared with the group before treatment, the difference was statistically significant (P < 0.05); while the serum tumor research after treatment the levels of markers was significantly lower than the control group, the difference was statistically significant (P < 0.05); There was no statistically significant difference in adverse reaction rates between the two groups (P > 0.05). Conclusion: Trastuzumab combined with ixabepilone for patients with metastatic breast cancer can reduce the CEA, CA125 and CA15-3 levels, and drug safety, has clinical value.
黄任平. 曲妥珠单抗联合伊沙匹隆治疗晚期转移性乳腺癌的疗效观察[J]. 河北医学, 2017, 23(10): 1598-1601.
HUANG Renping. Efficacy of Trastuzumab and Ixabepilone in the Treatment |of Advanced Metastatic Breast Cancer. 河北医学, 2017, 23(10): 1598-1601.
[1]胡爱玲.曲妥珠单抗联合含紫杉类方案治疗HER-2阳性晚期乳腺癌疗效观察[J].现代中西医结合杂志,2015(35):3948~3950. [2] 胡赛男,张莉莉.跨线曲妥珠单抗联合不同化疗方案治疗HER2阳性晚期乳腺癌的临床研究[J].肿瘤防治研究,2016,43(1):39~44. [3] 吴梅红,王梅,王薇,等.氟维司群联合曲妥珠单抗治疗芳香化酶抑制剂耐药的晚期LuminalB型(HER-2阳性)乳腺癌的疗效观察[J].临床肿瘤学杂志,2014(6):512~515. [4] Paladio-Hernández J, Martínez-Morales J. Cost-effectiveness of cardioprotective effect of dexrazoxane in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy in Mexico[J].Value in Health, 2015, 18(7):A454. [5] 夏秀林, 候林都, 闫有礼.拉帕替尼联合曲妥珠单抗治疗HER2阳性乳腺癌的疗效观察[J].现代药物与临床,2016,31(12):1988~1993. [6] 刘立川,袁欣.曲妥珠单抗联合紫杉醇治疗CerbB-2基因过表达的转移性乳腺癌[J].中国药物与临床,2014,14(2):248~249. [7] Altundag K, Basaran G, Oksuzoglu B, et al. PCN70 - Cost of treatment of HR+/HER2- post menopausal advanced/metastatic breast cancer patients in turkey[J].Value in Health, 2016, 19(3):A146. [8] 郭继红, 徐兵河,马飞,等.曲妥珠单抗联合不同化疗方案治疗人表皮生子因子受体2阳性晚期乳腺癌的疗效和安全性[J].中华肿瘤杂志,2014(5):372~376. [9] 李望,王涛,边莉,等.曲妥珠单抗联合卡培他滨一线解救治疗HER-2阳性复发转移性乳腺癌的疗效与安全性[J].中华医学杂志,2015,95(34):2796~2798. [10] 朱华云,孙小峰,陈嘉,等.曲妥珠单抗联合白蛋白结合型紫杉醇治疗晚期乳腺癌的疗效和安全性[J].徐州医学院学报,2015(11):752~755.
2017, Vol. 23 
冀公网安备13080202000677号